|Bid||43.38 x 3000|
|Ask||43.68 x 1000|
|Day's Range||43.16 - 45.20|
|52 Week Range||16.74 - 59.25|
|Beta (3Y Monthly)||2.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Two deals for two big Canadian marijuana producers were announced on the same day, and they hint as to why one of these marijuana stocks is the clear winner.
Ryan McQueeney and Maddy Johnson discuss earnings results from Netflix and the big U.S. banks. The hosts also remember the legacy of Jack Bogle and chat about several new cannabis industry deals.
Cannabis investors may be witnessing the rare birth of an entirely new industry , and one Wall Street analyst said Friday three companies will emerge as the leaders of the new cannabis market. The Analyst ...
HENDERSON, NV / ACCESSWIRE / January 18, 2019 / Cannabis remains one of the most volatile and intriguing sectors on the market. Several options in the space remain available at a bargain. One play that ...
Premier Health Group (OTC:PHGRF) (CSE:PHGI), HEXO Corp (OTC PINK: HYYDF), Canopy Growth Corp (CGC) (WEED.TO), and Cronos Group Inc (CRON) are for pot stocks worth keeping tabs on as we close out this week. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has seen impressive gains during the month of January, as the cannabis sector has garnered significant notoriety, as well as a major increase in public support. Earlier this week, Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced that as part of its international expansion strategy, it has entered into a strategic partnership with China'a 360 Health, a healthcare subsidiary of 360 Security Technology.
Canopy Growth Corporation (CGC) closed the most recent trading day at $42.77, moving +1.59% from the previous trading session.
Given that diseases are becoming more difficult to treat, it would seem that we are in desperate need of major advancements in healthcare technology, and many of these steps forward have been made possible through the advent of legalized medical marijuana. Towards the tail-end of last year, Canadian Prime Minister Justin Trudeau and members of the Canadian government agreed to legalize recreational/medicinal cannabis usage, resulting in a rush of energy for Canada's cannabis industry. With the global medical marijuana market predicted to reach $55.0 billion by 2024, according to a new research study published by Global Market Insights, Inc, it stands to reason that companies with the ability to combine the complex medical applications of cannabis with integrative healthcare frameworks could create potential opportunities from entering the nascent marijuana industry.
It's gimmicky to be sure. Yet, it's also brilliant. On Wednesday, New Age Beverages (NASDAQ:NBEV) unveiled a new line of cannabis-infused drinks that will utilize the name and fame of late reggae star Bob Marley to launch Marley+CBD. The agreement pairs a niche maker of teas and flavored waters with a well-known entertainer who is widely remembered as a fan of marijuana. The news wasn't terribly surprising, given the response from NBEV stock owners. Shares were up slightly in front of the announcement that a conference call had been scheduled to discuss then-unknown news, and New Age Beverages stock actually fell once investors learned of the new product and label. This is a development, however, that may need a slow burn to fully demonstrate the potential of a Marley-branded, cannabis-based drink. NBEV could be a good buy for investors interested in pot stocks, but hesitant about a pure-marijuana play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Sign of the Times In some regards this was inevitable. * 10 Growth Stocks With the Future Written All Over Them Last year was a huge year for cannabis, with sweeping legalization in Canada -- though cannabis drinks are not yet legal in Canada -- and legalization progress in the United States. Partnerships began taking shape in earnest, with some major names showing interest in the business without even knowing exactly how they could or should plug into the legalized marijuana market. Constellation Brands (NYSE:STZ) was arguably the first big name to take the plunge, making a modest investment in Canada's marijuana producer Canopy Growth (NYSE:CGC) early last year and then upping that investment to a $4 billion, 38% stake in August. Anheuser Busch (NYSE:BUD) forged its tie-up with Tilray (NASDAQ:TLRY) in December to explore the development of THC and CBD-infused beverages. Even PepsiCo (NASDAQ:PEP) has acknowledged it's mulling the possibility. ### Marley+CBD Enters a Crowded Market The first product to launch under the Marley+CBD label will be relaxation drink Mellow Mood, soon to be available Colorado, Oregon, Washington, and Michigan. The 15.5 ounce can will contain 25 milligrams of cannabidiol, which does not cause a 'high' like THC (tetrahydrocannabinol) does, but still offers a variety of physical benefits The company implied that more Marley+CBD beverages may be on the way. Investors shouldn't think, however, that New Age Beverages has beaten bigger, better-funded players to the market. The cannabis-based beverage market is already fairly crowded. Tinley, Level+, Dixie, Stillwater, Mood33, Mad Hatter and Brewbudz are just some of the brands of CBD and THC-infused drinks already available, where such beverages are legal. In fact, New Age itself already launched a cannabis-infused drink back in October. The existing and future competitors within the CBD beverage market are a reflection of growing demand. Still, the Marley name is a powerful one, as is the New Age Beverages moniker. ### Modest Market Size In 2017, it was estimated that the legal marijuana market was worth $9 billion.That was before Canada legalized it, and with only a handful of U.S. states on board. By 2022, as pot is legalized in more places, the market could grow to $23 billion. Of those figures, the vast majority of the money has been and will be spent on dry leaf, for smoking. Canaccord estimates that by 2022, the THC-infused beverage market will still only be worth $340 million per annum, while the CBD-infused drinks market will only be worth $260 million. And, cannabis-infused beverages are also expected to make up only a fifth of the entire edibles market. ### Bottom Line for NBEV Stock Though competitors lie ahead in what will indeed likely be a modestly-sized market, New Age Beverages has the advantage of an established distribution channel, at least a little influence within the industry and a brand name linked to a prolific supporter of marijuana that helped reduce the stigma of its use. * 7 Stocks to Buy as the Dollar Weakens In that light, New Age Beverages may have just become one of the top names to beat within the niche. Though NBEV stock hasn't responded especially well to the news yet, time could still prove the full potential of the new product to skeptical investors. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post Cannabis-Infused Drinks Are a Slow Burn for NBEV Stock appeared first on InvestorPlace.
It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its 0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it. Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.
Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (RIV.V) today announced that Narbe Alexandrian has been appointed as President of the Company, effective immediately. In this role, Narbe will lead the corporate development initiatives as well as manage the day-to-day business of the Company. “I believe that the team at Canopy Rivers has developed one of the most attractive and compelling platforms in the cannabis industry today,” said Narbe Alexandrian, newly appointed President of Canopy Rivers.
The marijuana tailwind has been great for the entire sector, but the most well-known companies got there for a reason. It hasn't received the same level of attention, but the neurology sector is seeing a similar tailwind. This is an immense $6 billion market opportunity in the coming years, and these companies are commanding big market valuations as a result.
Ryan McQueeney covers the latest Brexit news and Snap's executive exodus. He also recaps earnings results from Goldman Sachs, Bank of America, and United Air Lines. Later, he discusses a busy week for deals in the cannabis industry.
CORAL GABLES, FL / ACCESSWIRE / January 16,2019 / Marijuana stocks have been anything but safe over the course of the past year to two years, during the course of which top players in the cannabis industry saw huge boosts in investor interest. With the new year in full swing, Leafbuyer Technologies Inc (LBUY), New Age Beverages Corp (NBEV), Canopy Growth Corp (CGC) (WEED.TO), and Tilray Inc (TLRY) are 4 pot stocks that could make moves on Wednesday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.
The end of last year brought something not seen in a while--a bear market. As a result, many investors were reeling as stock prices--particularly in the tech industry--massively declined. However, when stocks decline, there is one silver lining that benefits cash-rich investors: cheap stocks. Many of the best stocks are now trading at low prices. Moreover, when companies with cheap stocks maintain or improve their growth rates, many investors often look to buy their shares. As we begin the new year, the following cheap stocks have those characteristics, leaving them well-positioned to skyrocket in the coming months and years. * 10 Growth Stocks With the Future Written All Over Them InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Cheap Stocks to Buy: Bank of America (BAC) More than ten years after the financial crisis, Bank of America (NYSE:BAC) is again on a list of cheap stocks. BAC has come a long way since it fell to $2.50 per share at the height of the crisis. Now, it trades at almost $29 per share. Moreover, it resumed annual increases of its dividend in 2014. Today, it returns 60 cents per share of dividends to its shareholders each year, yielding about 2.1%. However, the forward price-earnings ratio of about ten is what really makes BAC one of the best stocks. The multiple is well below the stock's five-year average of about 19. Also, companies whose stocks have single-digit PEs rarely generate double-digit profit increases, but BAC is in that category. Wall Street analysts on average expect the bank's profits to rise 10.6% this year. Moreover, according to the consensus estimate, BAC's average annual profit increase over the next five years will be 20.7%. The stock fell in 2018 amid a number of headwinds. Among these headwinds were the declining results of its investment banking unit, the negative market environment and fears of an inverted yield curve. However, amid these headwinds, Warren Buffett continues to buy BAC, indicating that the Oracle of Omaha considers it to be one of the best stocks in the market. Also, one can likely assume BAC has become his favorite bank stock. He now has a bigger position in BAC than in Wells Fargo (NYSE:WFC), which used to be his favorite bank stock. Assuming the economy doesn't nose dive, investors can, like Buffett, profit handsomely from one of the best stocks to buy in the market, BAC stock. ### Cheap Stocks to Buy: CannTrust (CNTTF) Although it's not among the more inexpensive stocks in the S&P 500, Canadian cannabis company CannTrust (OTCMKTS:CNTTF) makes the cheap stocks list because it's inexpensive compared to its peers in the marijuana industry. Unlike most cannabis companies, CannTrust is already profitable, and CNTTF stock has a forward price-earnings ratio of about 29.8. In an environment in which an industry leader, Canopy Growth (NYSE:CGC), trades at 100 times its sales, CNTTF is a screaming bargain and one of the best stocks in the market. Canadian marijuana stocks have suffered from a "sell the news" phenomenon since the companies' principal product became fully legal in their home market. However, CannTrust is poised to benefit from many trends. For one, it has applied for a listing on the New York Stock Exchange. Joining the Big Board should open up CNTTF stock to a new class of investors. Secondly, although cannabis remains on the list of Schedule 1 drugs in the U.S., the recent legislation that legalized hemp should give all Canadian marijuana firms a foothold in the U.S. market. The company's focus on pharma also provides the stock with another potential catalyst. CannTrust sent its first shipment of cannabis oil to Denmark in the third quarter of 2018. It has also entered the Asia-Pacific market, through a partnership with Australia-based Cannatrek. Consequently, even if the company fails to meaningfully penetrate the U.S. market, it still can benefit from overseas expansion. Furthermore, even though CannTrust's valuation is lower than that of its major peers, its growth should remain strong for the foreseeable future. On average, analysts predict that its profits will increase by almost 155% this year, making CNTTF a very cheap stock, despite its forward price-earnings ratio of nearly 30. As CannTrust moves into other developed countries and possibly the U.S., a revived interest in cannabis should enable its valuation to catch up with that of its peers. ### Cheap Stocks to Buy: Intel (INTC) Few PC-era stocks have suffered as much as Intel (NASDAQ:INTC) has. Once the world's largest chip maker, Intel stagnated as consumers increasingly turned away from PCs. Intel's PC-era peers such as Microsoft (NASDAQ:MSFT), Nvidia (NASDAQ:NVDA), and even AMD (NASDAQ:AMD) built new business lines and resumed growing. However, INTC stock continued to languish. The high turnover of its top management, as well as security-related issues, also weighed on Intel stock. However, INTC looks ready to again become one of the best stocks to buy in tech. The company has invested heavily in data-center technology. As a result, its Data Center group appears poised to overtake its PC Client group in size over the next few years. Due to Intel's purchase of Mobileye, INTC has become a leader in the autonomous-vehicle market. That, along with the company's Internet of Things (IoT) products, should help INTC stock rise. And as the advent of 5G makes more advanced applications possible, Intel will benefit even more from these trends. INTC is a cheap stock due to its price-earnings multiple. It trades at a forward PE ratio of about 10.6, showing that investors have yet to fully appreciate Intel's comeback. Due to a temporary glut of chips, Intel 's profit growth will be slow this year. However, its profits should resume growing by double-digit percentage rates in 2020. Once investors begin to realize that Intel has resumed a leadership role in the tech industry making it one of the best stocks in the market, it should again command valuations comparable to its peers in big tech. As of this writing, Will Healy is long CNTTF. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Cheap Stocks to Buy (Before They Skyrocket) appeared first on InvestorPlace.
The New York State has granted Canopy Growth Corp. (NYSE: CGC) a license to process and produce hemp. The company plans to invest between $100 million and $150 to establish a hemp industrial park somewhere in the state. Canopy is happy with the current New York political leadership that supports the cannabis business. Canopy Co-CEO […] The post Canopy Growth (NYSE: CGC) to Build $100-150 Hemp Plant in New York appeared first on Market Exclusive.
Cannabis News Cannabis producer FoliuMed has completed the construction of its first greenhouses on a 16-hectare grow site near Bogota, Colombia. In an area spanning 20 soccer fields, FoliuMed will produce over 70 tons of medicinal hemp and cannabis plants in 150 greenhouses. The plants will be processed into oils and sold as pharma-grade ingredients […] The post Cannabis Stock News Daily Roundup January 16 appeared first on Market Exclusive.